Yohann Loriot MD, MS, PhD

Dr. Yohann Loriot is a deputy head of the early trials department at Gustave Roussy. Dr. Loriot’s major research focus involves the study of molecular mechanisms mediating the progression to lethal disease in bladder and prostate cancer and the use of this information to develop novel strategies and therapies. Dr Loriot is currently a member of the steering committee of multiple international clinical trials from phase I to phase III leading him to be co-author of collaborative work (published in N Engl J Med, Nature, Lancet Oncology, European Urology, J Clin Oncol). He has been involved in trials leading to several drug approvals (enzalutamide, abiraterone, atezolizumab). He’s now developing ancillary studies to better understand the mechanisms of actions and resistance to these new drugs (targeted therapies and checkpoint inhibitors) (MATCH-R study).